Anticoagulation in Patients Suffering From COVID-19 Disease The ANTI-CO Trial

• Status: Recruiting
• Trial end date: 2021-03-28
• Target enrollment: 0
• Participant gender: All

Summary

Patients with COVID-19 associated ARDS and mechanical ventilation have a high mortality. Part of the disease is an activation of the coagulation system which seems to contribute to clotformation in the pulmonary bloodstream. Recently we implemented an algorithm applying higher doses of heparins (LMWH). However, this approach could not inhibit clotformation enough. Bivalirudin could prevent clotformation better and support dissolving existing clots.

Therefore, we want to compare 50 patients with the standard treatment with 50 patients under bivalirudin treatment which we normally apply in patients with a HIT-syndrome.

Our primary outcome measure is oxygenation reflected as P/F ratio.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hamad Medical Corporation
• Treatments: Bivalirudin

Criteria

Inclusion Criteria:

• Adult patient (≥ 18 years of age)

• Positive COVID-test

• Under mechanical ventilation

• D-Dimers>1.2 mg/L

Exclusion Criteria:

• Pregnancy

• Allergy to the drug (bivalirudin)

• Inherited coagulation abnormalities

• No informed consent